4BIO Capital

General contacts
Investor type

PE / VC

Founded

2014

AUM

$200 M

Location

Russia

Investment Ticket

$5-10 m

Investment Stage

Seed Series A

Region of investment

Europe North America Asia

ESG Focus

Impact investor
Investor profile last updated: 10 December, 2021

Profile

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.

4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.

The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.

Industry

Life Sciences MedTech Biotechnology

Contacts

Name
Title
Email
Social Networks
avatar
Andrey Kozlov Managing Partner
Managing Partner
a•••@•••
LinkedIn
avatar
Owen Smith Investment Director
Investment Director
o•••@•••
LinkedIn
Upgrade to see contacts
avatar
fHdIwvDTx6Kyjc5O fHdIwvDTx6Kyjc5O
fHdIwvDTx6Kyjc5O
fHdIwvDTx6Kyjc5O@fHdIwvDTx6Kyjc5O.com
linkedin twitter
avatar
fHdIwvDTx6Kyjc5O fHdIwvDTx6Kyjc5O
fHdIwvDTx6Kyjc5O
fHdIwvDTx6Kyjc5O@fHdIwvDTx6Kyjc5O.com
linkedin twitter
avatar
fHdIwvDTx6Kyjc5O fHdIwvDTx6Kyjc5O
fHdIwvDTx6Kyjc5O
fHdIwvDTx6Kyjc5O@fHdIwvDTx6Kyjc5O.com
linkedin twitter
Investment-team contacts for 4BIO Capital — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about 4BIO Capital

4BIO Capital is a venture capital and private equity firm. It backs companies at Seed and Series A, writing tickets of $5-10 m.
4BIO Capital is located in Russia.
4BIO Capital was founded in 2014.
4BIO Capital invests in companies and startups in Life Sciences, MedTech, Biotechnology.
4BIO Capital invests in companies and startups in Europe, North America, Asia.
4BIO Capital invests in companies and startups at Seed, Series A.
4BIO Capital usually invests $5-10 m on average.
4BIO Capital has around $200m assets under management.
Yes, 4BIO Capital is impact investor.
4BIO Capital can be reached through its website 4biocapital.com, its LinkedIn page and its X account. Its general enquiries address is info@4biocapital.com. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for 4BIO Capital — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query 4BIO Capital directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 10 December, 2021. Something out of date here? Report it — we re-run that firm within 48h and get back to you.